Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
Multiple Myeloma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 106 (final count)
- Started
- Jun 8, 2020
- Main results expected
- Apr 17, 2025
- Fully finished
- Mar 11, 2027
- Results posted
- May 6, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
DE Phase: Number of Participants With Dose Limiting Toxicities (DLTs)
Measured over: Up to 28 days
DE Phase: Number of Participants With Adverse Events (AEs)
Measured over: Up to approximately 253 weeks
DE Phase: Number of Participants With Worst-case Hematology Results by Maximum Grade Increase Post - Baseline Relative to Baseline
Measured over: Baseline (Day 1) and up to approximately 253 weeks
DE Phase: Number of Participants With Worst-Case Chemistry Results by Maximum Grade Increase Post - Baseline Relative to Baseline
Measured over: Baseline (Day 1) and up to approximately 253 weeks
CE Phase: Overall Response Rate (ORR)
Measured over: Up to approximately 253 weeks
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07084896 · record last updated 2026-05-06 · checked 2026-11-09 15:47 UTC